Docking to Erlotinib Off-Targets Leads to Inhibitors of Lung Cancer Cell Proliferation with Suitable in Vitro Pharmacokinetics
- 25 May 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 1 (5) , 229-233
- https://doi.org/10.1021/ml100031a
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A small-cell lung cancer genome with complex signatures of tobacco exposureNature, 2009
- BioDrugScreen: a computational drug design resource for ranking molecules docked to the human proteomeNucleic Acids Research, 2009
- Targeting the Human Cancer Pathway Protein Interaction Network by Structural GenomicsMolecular & Cellular Proteomics, 2008
- Novel paradigms for drug discovery: computational multitarget screeningTrends in Pharmacological Sciences, 2008
- Cancer: A Systems Biology diseaseBiosystems, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Unsupervised Data Base Clustering Based on Daylight's Fingerprint and Tanimoto Similarity: A Fast and Automated Way To Cluster Small and Large Data SetsJournal of Chemical Information and Computer Sciences, 1999
- Cytotoxicity and antitumor activities of fungal bis(naphtho-.GAMMA.-pyrone) derivatives.Journal of Pharmacobio-Dynamics, 1988
- Chaetoglobosins, cytotoxic 10-(indol-3-yl)-(13)cytochalasans from Chaetomium spp. I. Production, isolation and some cytological effects of chaetoglobosins A-J.CHEMICAL & PHARMACEUTICAL BULLETIN, 1982
- Pyrimidines. XXII. 2,4-Diamino-6-arylamino-5-pyrimidinecarboxaldehydes and related compoundsJournal of Medicinal Chemistry, 1968